AVCO
Avalon GloboCare Corp. [AVCO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AVCO Stock Summary
In the News
Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition
Avalon GloboCare Corp (NASDAQ:ALBT) has encouraged its shareholders to vote on a number of key proposals at its upcoming annual meeting to be held on December 29, 2022, at 11am Eastern Time. Shareholders can vote on a new proposed board composition to reflect the company's continued US focus and acquisition of Laboratory Services MSO LLC, Avalon said in a statement.
Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M
Avalon GloboCare Corp (NASDAQ:AVCO) is set to buy a 60% stake in Laboratory Services MSO as it expands its focus on lab testing and services in what it called a 'transformative' deal worth $31 million. California-headquartered Laboratory Services has completed over 600,000 tests since inception.
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now
What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform
Avalon GloboCare Corp (NASDAQ:AVCO) has received a notice of allowance from the US Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The company's QTY code is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development, the company said.
Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews
Avalon GloboCare Corp (NASDAQ:AVCO) said that an article featuring its QTY protein code technology was published in Chemical Reviews, the official journal of the American Chemical Society. The publication, titled “Protein Design: From the Aspect of Water Solubility and Stability,” discusses the innovative QTY protein design code, which Avalon co-designed, as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications.
Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer
Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could accelerate development of therapeutic monoclonal antibodies to treat cancer. Developed by Avalon, the QTY code technology is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins for use in clinical applications, including drug development.
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City.
Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments
Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision companion diagnostics for chimeric antigen receptor (CAR)-T cell therapies, the company announced. LDHI is a hematology research institute based in Beijing developing precision diagnostics based on personalized genomic, proteomic, transcriptomic and metabolomic platforms.
Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials
Avalon GloboCare Corp (NASDAQ:AVCO) has revealed that is has filed 16 patent applications related to novel cellular therapies and related technologies as the company moves towards clinical trials. The company said the patents were filed with US Patent and Trademark Office, the China National Trademark Office, and under the Patent Cooperation Treaty covering 36 countries.
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
AVCO Financial details
AVCO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.22 | 0.21 | 0.17 | 0.16 | 0.13 | |
| Net income per share | -1.08 | -2.41 | -1.61 | -1.09 | -1.36 | |
| Operating cash flow per share | -0.61 | -0.94 | -0.95 | -0.59 | -0.75 | |
| Free cash flow per share | -0.63 | -0.99 | -0.95 | -0.59 | -0.75 | |
| Cash per share | 0.31 | 0.1 | 0.09 | 0.1 | 0.21 | |
| Book value per share | 1.68 | 0.59 | 0.52 | 0.36 | 1.2 | |
| Tangible book value per share | 1.39 | 0.59 | 0.52 | 0.36 | 1.2 | |
| Share holders equity per share | 1.68 | 0.59 | 0.52 | 0.36 | 1.2 | |
| Interest debt per share | 0.33 | 0.44 | 0.49 | 0.41 | 0.87 | |
| Market cap | 198.01M | 144.98M | 89.05M | 69.63M | 48.51M | |
| Enterprise value | 196.76M | 147.4M | 92.06M | 72.12M | 51.09M | |
| P/E ratio | -25.47 | -8.01 | -6.96 | -7.54 | -3.83 | |
| Price to sales ratio | 126.74 | 93.76 | 64.63 | 50.06 | 40.35 | |
| POCF ratio | -45.04 | -20.48 | -11.8 | -13.86 | -6.89 | |
| PFCF ratio | -43.91 | -19.44 | -11.8 | -13.81 | -6.89 | |
| P/B Ratio | 16.34 | 32.47 | 21.63 | 22.57 | 4.35 | |
| PTB ratio | 16.34 | 32.47 | 21.63 | 22.57 | 4.35 | |
| EV to sales | 125.94 | 95.32 | 66.82 | 51.85 | 42.5 | |
| Enterprise value over EBITDA | -27.68 | -7.99 | -7.59 | -8.53 | -7.16 | |
| EV to operating cash flow | -44.76 | -20.82 | -12.2 | -14.35 | -7.26 | |
| EV to free cash flow | -43.64 | -19.77 | -12.2 | -14.3 | -7.26 | |
| Earnings yield | -0.04 | -0.12 | -0.14 | -0.13 | -0.26 | |
| Free cash flow yield | -0.02 | -0.05 | -0.08 | -0.07 | -0.15 | |
| Debt to equity | 0.17 | 0.71 | 0.91 | 1.07 | 0.41 | |
| Debt to assets | 0.15 | 0.3 | 0.36 | 0.32 | 0.23 | |
| Net debt to EBITDA | 0.18 | -0.13 | -0.25 | -0.29 | -0.36 | |
| Current ratio | 3.18 | 0.55 | 0.5 | 0.3 | 0.66 | |
| Interest coverage | -24.25 | -221.54 | -73.8 | -44.06 | -2.08 | |
| Income quality | 0.55 | 0.39 | 0.6 | 0.55 | 0.59 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.92 | 10.95 | 8.68 | 5.91 | 4.71 | |
| Research and developement to revenue | 0 | 1.15 | 0.64 | 0.74 | 0.61 | |
| Intangibles to total assets | 0.09 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.05 | 0 | 0 | 0 | |
| Capex to revenue | -0.07 | -0.24 | 0 | -0.01 | 0 | |
| Capex to depreciation | -0.22 | -0.74 | 0 | -0.04 | 0 | |
| Stock based compensation to revenue | 1.98 | 5.96 | 3.99 | 1.52 | 0.92 | |
| Graham number | 6.39 | 5.68 | 4.33 | 2.98 | 6.05 | |
| ROIC | -0.52 | -2.4 | -1.57 | -1.37 | -0.5 | |
| Return on tangible assets | -0.64 | -1.73 | -1.23 | -0.9 | -0.64 | |
| Graham Net | 0.02 | -0.64 | -0.66 | -0.72 | -0.7 | |
| Working capital | 2.48M | -1.26M | -1.31M | -3.08M | -1.21M | |
| Tangible asset value | 10M | 4.47M | 4.12M | 3.08M | 11.16M | |
| Net current asset value | 1.48M | -4.45M | -4.96M | -5.83M | -6.22M | |
| Invested capital | 0.17 | 0.71 | 0.91 | 1.07 | 0.41 | |
| Average receivables | 50.44K | 148.06K | 139.64K | 51.31K | 100.92K | |
| Average payables | 3.36K | 45.51K | 42.16K | 0 | 0 | |
| Average inventory | 7.83K | 258.58K | 498.71K | 461.62K | 214.99K | |
| Days sales outstanding | 12.2 | 57.57 | 9.38 | 17.64 | 40.87 | |
| Days payables outstanding | 2.08 | 25.51 | 0 | 0 | 0 | |
| Days of inventory on hand | 4.04 | 152.54 | 182.31 | 160.72 | 0 | |
| Receivables turnover | 29.92 | 6.34 | 38.93 | 20.69 | 8.93 | |
| Payables turnover | 175.4 | 14.31 | 0 | 0 | 0 | |
| Inventory turnover | 90.37 | 2.39 | 2 | 2.27 | 0 | |
| ROE | -0.64 | -4.05 | -3.11 | -2.99 | -1.14 | |
| Capex per share | -0.02 | -0.05 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Net income per share | -0.95 | -0.28 | -0.58 | -0.25 | -0.14 | |
| Operating cash flow per share | -0.25 | -0.21 | -0.18 | -0.25 | -0.12 | |
| Free cash flow per share | -0.25 | -0.21 | -0.19 | -0.25 | -0.12 | |
| Cash per share | 0.41 | 0.21 | 0.09 | 0.06 | 0.03 | |
| Book value per share | 0.47 | 1.2 | 1.99 | 1.77 | 1.56 | |
| Tangible book value per share | 0.47 | 1.2 | 1.99 | 1.77 | 1.56 | |
| Share holders equity per share | 0.47 | 1.2 | 1.99 | 1.77 | 1.56 | |
| Interest debt per share | 0.81 | 0.51 | 0.57 | 0.77 | 0.79 | |
| Market cap | 62.2M | 48.51M | 19.83M | 15.78M | 8.66M | |
| Enterprise value | 62.86M | 51.09M | 24.5M | 22.72M | 16.42M | |
| P/E ratio | -1.68 | -4.66 | -0.86 | -1.55 | -1.46 | |
| Price to sales ratio | 195.97 | 163.7 | 66.96 | 51.42 | 26.15 | |
| POCF ratio | -26.07 | -24.7 | -10.81 | -6.25 | -6.42 | |
| PFCF ratio | -26.07 | -24.7 | -10.69 | -6.25 | -6.42 | |
| P/B Ratio | 13.59 | 4.35 | 1 | 0.87 | 0.51 | |
| PTB ratio | 13.59 | 4.35 | 1 | 0.87 | 0.51 | |
| EV to sales | 198.06 | 172.42 | 82.73 | 74.04 | 49.58 | |
| Enterprise value over EBITDA | -34.42 | -23.6 | -9.68 | -12.73 | -15.47 | |
| EV to operating cash flow | -26.34 | -26.01 | -13.35 | -9 | -12.18 | |
| EV to free cash flow | -26.34 | -26.01 | -13.21 | -8.99 | -12.18 | |
| Earnings yield | -0.15 | -0.05 | -0.29 | -0.16 | -0.17 | |
| Free cash flow yield | -0.04 | -0.04 | -0.09 | -0.16 | -0.16 | |
| Debt to equity | 1.01 | 0.41 | 0.28 | 0.42 | 0.48 | |
| Debt to assets | 0.36 | 0.23 | 0.18 | 0.25 | 0.27 | |
| Net debt to EBITDA | -0.36 | -1.19 | -1.84 | -3.89 | -7.31 | |
| Current ratio | 1.34 | 0.66 | 0.27 | 0.24 | 0.13 | |
| Interest coverage | -0.48 | -16.02 | -17.05 | -7.57 | -2.6 | |
| Income quality | 0.44 | 0.81 | 0.66 | 0.99 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.22 | 5.3 | 6.51 | 5.58 | 3.32 | |
| Research and developement to revenue | 0.54 | 0.64 | 0.31 | 0.06 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.07 | -0.01 | 0 | |
| Capex to depreciation | 0 | 0 | -0.21 | -0.02 | 0 | |
| Stock based compensation to revenue | 0.51 | 0.42 | 1.1 | 1.76 | 0.57 | |
| Graham number | 3.18 | 2.74 | 5.08 | 3.14 | 2.2 | |
| ROIC | -0.29 | -0.15 | -0.21 | -0.09 | -0.07 | |
| Return on tangible assets | -0.72 | -0.13 | -0.19 | -0.08 | -0.05 | |
| Graham Net | -0.44 | -0.7 | -0.99 | -1.11 | -1.16 | |
| Working capital | 1.12M | -1.21M | -3.79M | -4.54M | -5.83M | |
| Tangible asset value | 4.58M | 11.16M | 19.91M | 18.15M | 16.82M | |
| Net current asset value | -3.88M | -6.22M | -9.67M | -11M | -12.28M | |
| Invested capital | 1.01 | 0.41 | 0.28 | 0.42 | 0.48 | |
| Average receivables | 112.76K | 128.43K | 134.19K | 134.9K | 126.36K | |
| Average payables | 228.49K | 40.29K | 0 | 0 | 0 | |
| Average inventory | 236.65K | 69.59K | 165.09K | 456.84K | 452.8K | |
| Days sales outstanding | 34.66 | 40.89 | 40.64 | 39.9 | 31.69 | |
| Days payables outstanding | 29.34 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 50.68 | 0 | 119.61 | 213.99 | 100.63 | |
| Receivables turnover | 2.6 | 2.2 | 2.21 | 2.26 | 2.84 | |
| Payables turnover | 3.07 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 1.78 | 0 | 0.75 | 0.42 | 0.89 | |
| ROE | -2.02 | -0.23 | -0.29 | -0.14 | -0.09 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
AVCO Frequently Asked Questions
What is Avalon GloboCare Corp. stock symbol ?
Avalon GloboCare Corp. is a US stock , located in Freehold of New jersey and trading under the symbol AVCO
What is Avalon GloboCare Corp. stock quote today ?
Avalon GloboCare Corp. stock price is $0.5259 today.
Is Avalon GloboCare Corp. stock public?
Yes, Avalon GloboCare Corp. is a publicly traded company.
Company Profile
- Volume Average 189.95K
- Market Capitalization 5.26M
- Employee 5
- CEO Dr. David K. Jin
- Headquarters Freehold,NEW JERSEY,US
- IPO Date 2016-02-22
-
Website
https://www.avalon-globocare.com 
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
